

# Influenza A Virus H3N2 Subtype Infections R&D Pipeline Analysis Report, Q4 2020

<https://marketpublishers.com/r/IF725315800EEN.html>

Date: October 2020

Pages: 165

Price: US\$ 2,199.00 (Single User License)

ID: IF725315800EEN

## Abstracts

### Influenza A Virus H3N2 Subtype Infections Pipeline Overview

The Q4 Influenza A Virus H3N2 Subtype Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Influenza A Virus H3N2 Subtype Infections, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.

### Influenza A Virus H3N2 Subtype Infections Disease Types, Symptoms, Causes, and Available Treatment Options

The comprehensive report on the indication presents Influenza A Virus H3N2 Subtype Infections disease overview, Influenza A Virus H3N2 Subtype Infections types, Influenza A Virus H3N2 Subtype Infections symptoms, causes, and FDA/EMA approved treatment options.

### Influenza A Virus H3N2 Subtype Infections Pipeline Trends and Insights

The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Influenza A Virus H3N2 Subtype Infections indication. The report presents near-term and long-term pipeline development trends and potential insights.

### Influenza A Virus H3N2 Subtype Infections Company Trends and Insights

The report analyzes the development progress, current status, investments, partnerships, and other developments of 33 companies. Business profiles and contact details of the companies actively perusing Influenza A Virus H3N2 Subtype Infections pipeline are assessed.

## Influenza A Virus H3N2 Subtype Infections R&D Pipeline Development Phase Trends and Insights

From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Influenza A Virus H3N2 Subtype Infections discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.

## Small Influenza A Virus H3N2 Subtype Infections companies look for licensing and collaboration partners

High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Influenza A Virus H3N2 Subtype Infections pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.

## Influenza A Virus H3N2 Subtype Infections Pipeline Market News and Developments during 2020

The Influenza A Virus H3N2 Subtype Infections industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.

## Influenza A Virus H3N2 Subtype Infections Mechanism of Action and Targets

Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.

## New molecular entity details

Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.

## Sources and Research Methodology

Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.

## Scope and Coverage

Influenza A Virus H3N2 Subtype Infections pipeline development activities

across the early phase, mid-stage, and late phase pipelines including therapeutic candidates

Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.

Company-company partnerships, company-institute partnerships, and investment details of companies are included

33 companies are included including AbbVie Inc, Adimmune Corp, Alla Chem LLC, Allergy Therapeutics Plc, Ansun Biopharma Inc, Aphios Corp, AstraZeneca Plc, AusBio Ltd, BiondVax Pharmaceuticals Ltd, BlueWillow Biologics Inc, Brandenburg Antiinfektiva GmbH, Changchun Bcht Biotechnology Co Ltd, Chicago Biosolutions Inc, Cidara Therapeutics Inc, ContraFect Corp, Emergent BioSolutions Inc, FluGen Inc, Gamma Vaccines Pty Ltd, ILiAD Biotechnologies LLC, Inovio Pharmaceuticals Inc, InvVax Inc, Janssen Pharmaceuticals, Jiangsu Kanion Pharmaceutical Co Ltd, Medicago Inc, NanoViricides Inc, New Amsterdam Sciences Inc, Novavax Inc, PrEP Biopharm Ltd, Sanofi, Sciogen Inc, Seqirus Ltd, Serum Institute of India Ltd, Vacthera BioTech GmbH,

Disease overview, Pipeline trends, market analysis, and other developments

Potential licensing/new business opportunities in Influenza A Virus H3N2 Subtype Infections pipeline market

## Highlights

Global coverage of companies and pipeline agents

2020 Trends, market analysis, and developments

Potential growth opportunities

Comprehensive details of drug candidates

## Reasons to Buy

Drive pipeline research and commercial assessment

Assess most promising drug candidates and stay ahead of the competition

Strengthen your pipeline through identifying business expansion and acquisition opportunities

Develop new candidates based on most focused targets and mechanism of actions

## Contents

### **1. TABLE OF CONTENTS**

- 1.1 List of Tables
- 1.2 List of Figures

### **2. INFLUENZA A VIRUS H3N2 SUBTYPE INFECTIONS PIPELINE TRENDS AND INSIGHTS**

- 2.1 Dominant Phase type of Influenza A Virus H3N2 Subtype Infections Pipeline, 2020
- 2.2 Most focused Mechanism of Action in Influenza A Virus H3N2 Subtype Infections Pipeline
- 2.3 Leading type of Route of Administration during 2020
- 2.4 Proportion of New Molecular Entities in Influenza A Virus H3N2 Subtype Infections pipeline
- 2.5 Active Companies Developing Influenza A Virus H3N2 Subtype Infections pipeline

### **3. INFLUENZA A VIRUS H3N2 SUBTYPE INFECTIONS DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS**

- 3.1 Disease Overview
- 3.2 Types
- 3.3 Symptoms
- 3.4 Approved Treatment Options

### **4. INFLUENZA A VIRUS H3N2 SUBTYPE INFECTIONS PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS**

- 4.1 AbbVie Inc
  - Adimmune Corp
  - Alla Chem LLC
  - Allergy Therapeutics Plc
  - Ansun Biopharma Inc
  - Aphios Corp
  - AstraZeneca Plc
  - AusBio Ltd
  - BiondVax Pharmaceuticals Ltd

BlueWillow Biologics Inc  
Brandenburg Antiinfektiva GmbH  
Changchun Bcht Biotechnology Co Ltd  
Chicago Biosolutions Inc  
Cidara Therapeutics Inc  
ContraFect Corp  
Emergent BioSolutions Inc  
FluGen Inc  
Gamma Vaccines Pty Ltd  
ILiAD Biotechnologies LLC  
Inovio Pharmaceuticals Inc  
InvVax Inc  
Janssen Pharmaceuticals  
Jiangsu Kanion Pharmaceutical Co Ltd  
Medicago Inc  
NanoViricides Inc  
New Amsterdam Sciences Inc  
Novavax Inc  
PrEP Biopharm Ltd  
Sanofi  
Sciogen Inc  
Seqirus Ltd  
Serum Institute of India Ltd  
Vacthera BioTech GmbH

## **5. INFLUENZA A VIRUS H3N2 SUBTYPE INFECTIONS PIPELINE DRUG PROFILES**

### 5.1 Current Status of Drug and Vaccine Candidates

#### 5.2 Drug Snapshot

##### 5.2.1 Drug

##### 5.2.2 Mechanism of Action

##### 5.2.3 Phase

##### 5.2.4 Co-Developer

##### 5.2.5 Originator

##### 5.2.6 Synonym

##### 5.2.7 Route of Administration

##### 5.2.8 Type of Molecule

##### 5.2.9 Orphan Drug Status

##### 5.2.10 New Molecular Entity

5.2.11 Area

5.3 Drug Details

5.4 Mechanism of Action

5.5 Licensing/Collaboration Agreements

5.6 Clinical Trial Details

## **6. INFLUENZA A VIRUS H3N2 SUBTYPE INFECTIONS PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020**

### **7. APPENDIX**

7.1 About the Publisher

7.2 Sources and Research Methodology

## I would like to order

Product name: Influenza A Virus H3N2 Subtype Infections R&D Pipeline Analysis Report, Q4 2020

Product link: <https://marketpublishers.com/r/IF725315800EEN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IF725315800EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970